Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the DESTINY-Breast04 trial data, but adding the DESTINY-Breast06 data to the label ...

The Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion [human] 10% solution) as a replacement therapy for primary humoral immunodeficiency (PI) in adult ...

Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers ...

Proton therapy is a type of external beam radiation therapy that delivers high dose radiation directly to cancer cells. Learn about its benefits and uses for breast cancer treatment.

Dive Brief: Sage Therapeutics will lay off 338 employees, the vast majority of its workforce, while in the process of being acquired by Supernus Pharmaceuticals, according to a Massachusetts ...